Dirucotide trials for secondary progressive MS discontinued for lack of efficacy
Lilly and BioMS Medical reported that their investigational agent dirucotide did not meet the primary end point of delaying disease progression in patients with secondary progressive multiple sclerosis (SPMS) in the phase 3 MAESTRO-01 trial.
Lilly and BioMS Medical reported that their investigational agent dirucotide did not meet the primary end point of delaying disease progression in patients with secondary progressive multiple sclerosis (SPMS) in the phase 3 MAESTRO-01 trial. Dirucotide and placebo also did not differ significantly on any secondary end points in the trial.
The companies have announced that they are discontinuing ongoing clinical trials of dirucotide for the treatment of SPMS (including MAESTRO-02 and MAESTRO-03) and will review the available data before deciding on how to move forward.
No unexpected safety or tolerability issues were reported in the MAESTRO-01 trial.
FDA granted dirucotide fast-track status for the treatment of SPMS in September 2008.
FDA Accepts NDA for Zoliflodacin, Potentially First Gonorrhea Antibiotic in Decades
June 13th 2025The FDA has accepted a New Drug Application for zoliflodacin, a first-in-class oral antibiotic for treating uncomplicated gonorrhea, offering a potential new option amid rising antibiotic resistance.
Read More
